KR20160097310A - 알파, 오메가 이치환된 디하이드록시 사이클로펜틸 화합물의 고체 형태 및 이의 제조방법 및 용도 - Google Patents

알파, 오메가 이치환된 디하이드록시 사이클로펜틸 화합물의 고체 형태 및 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR20160097310A
KR20160097310A KR1020167018489A KR20167018489A KR20160097310A KR 20160097310 A KR20160097310 A KR 20160097310A KR 1020167018489 A KR1020167018489 A KR 1020167018489A KR 20167018489 A KR20167018489 A KR 20167018489A KR 20160097310 A KR20160097310 A KR 20160097310A
Authority
KR
South Korea
Prior art keywords
crystalline form
compound
crystalline
thienyl
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167018489A
Other languages
English (en)
Korean (ko)
Inventor
커 우
죄르지 앰브러스
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20160097310A publication Critical patent/KR20160097310A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y10S514/913—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167018489A 2013-12-13 2014-12-12 알파, 오메가 이치환된 디하이드록시 사이클로펜틸 화합물의 고체 형태 및 이의 제조방법 및 용도 Ceased KR20160097310A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915575P 2013-12-13 2013-12-13
US61/915,575 2013-12-13
PCT/US2014/070156 WO2015089475A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
KR20160097310A true KR20160097310A (ko) 2016-08-17

Family

ID=52282957

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167018489A Ceased KR20160097310A (ko) 2013-12-13 2014-12-12 알파, 오메가 이치환된 디하이드록시 사이클로펜틸 화합물의 고체 형태 및 이의 제조방법 및 용도

Country Status (16)

Country Link
US (2) US9353079B2 (https=)
EP (1) EP3080096A1 (https=)
JP (2) JP2016539994A (https=)
KR (1) KR20160097310A (https=)
CN (1) CN105814033B (https=)
AU (1) AU2014361794B2 (https=)
BR (1) BR112016013594A8 (https=)
CA (1) CA2933556A1 (https=)
CL (2) CL2016001448A1 (https=)
IL (2) IL245917B (https=)
MX (1) MX2016007717A (https=)
RU (1) RU2730520C2 (https=)
SA (1) SA516371307B1 (https=)
SG (2) SG11201604787SA (https=)
UA (1) UA121108C2 (https=)
WO (1) WO2015089475A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2019023211A1 (en) 2017-07-25 2019-01-31 Allergan, Inc. SOLID COMPLEX COMPRISING (Z) -7 - ((1R, 2R, 3R, 5S) -2 - ((S, E) -5- (2,5-DICHLOROTHIOPHEN-3-YL) -3-HYDROXYPENT-1 EN-1-YL) -3,5-DIHYDROXYCYCLOPENTYL) HEPT-5-ENAMIDE, PREPARATION THEREOF AND USES THEREOF
WO2021152473A1 (en) * 2020-01-29 2021-08-05 Kci Licensing, Inc. Multiple fluid pathway connector with foam supports

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES416865A1 (es) * 1972-07-13 1976-03-01 Pfizer Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15.
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6602900B2 (en) * 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1996036599A1 (en) * 1995-05-18 1996-11-21 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension

Also Published As

Publication number Publication date
US9353079B2 (en) 2016-05-31
IL245917A0 (en) 2016-08-02
CL2016001448A1 (es) 2017-03-03
SG10201709702UA (en) 2018-01-30
WO2015089475A1 (en) 2015-06-18
RU2730520C2 (ru) 2020-08-24
US20170087163A1 (en) 2017-03-30
US20150166504A1 (en) 2015-06-18
SG11201604787SA (en) 2016-07-28
IL283810A (en) 2021-07-29
CN105814033A (zh) 2016-07-27
UA121108C2 (uk) 2020-04-10
JP2016539994A (ja) 2016-12-22
EP3080096A1 (en) 2016-10-19
CL2019000471A1 (es) 2019-07-12
SA516371307B1 (ar) 2018-10-04
AU2014361794B2 (en) 2019-04-04
CN105814033B (zh) 2019-10-25
JP2020073513A (ja) 2020-05-14
AU2014361794A1 (en) 2016-06-16
IL245917B (en) 2021-06-30
MX2016007717A (es) 2016-09-09
BR112016013594A2 (https=) 2017-08-08
BR112016013594A8 (pt) 2020-05-19
CA2933556A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
EP3636263B1 (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
WO2017167180A1 (zh) 沃替西汀的帕莫酸盐及其晶型
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
JP5550644B2 (ja) （１ｒ，２ｓ，３ｒ）−１−（２−（イソオキサゾール−３−イル）−１ｈ−イミダゾール−４−イル）ブタン−１，２，３，４−テトラオールの固体形態及びその使用方法
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
PL186411B1 (pl) Pochodne 3,4-dipodstawionego fenyloetanoloaminotetralinokarboksyamidu, kompozycja farmaceutyczna zawierająca te pochodne, zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej oraz zastosowanie tych pochodnych jako środka leczniczego
EP2528908B1 (en) Therapeutic agents for treatment of ocular hypertension
TWI659041B (zh) 類固醇樣化合物之多晶型形式以及其製備方法及用途
HK1227389A1 (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
HK1227410A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
HK1227389B (zh) α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法
UA76609C2 (en) 4-(diarylmethyl)-1-piperazinyl derivatives
EP3730143A1 (en) Omidenepag combination
CN103764622A (zh) N,n-二烷基亚烷基酯、其组合物以及其使用方法
HK40028884A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK40028884B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK40029828A (en) Omidenepag combination

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160708

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210628

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211015

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210628

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I